Acute Bacterial Skin And Skin Structure Infections Market Report 2024-2033: Size, Trends, Analysis, Insights, and Overview

Overview and Scope

Acute bacterial skin and skin structure infections (ABSSSIs) are a type of skin infection caused by bacteria that affect the skin and underlying tissues, leading to symptoms such as redness, swelling, pain, and warmth in the affected area. Medical interventions, such as antibiotic treatment, are used to prevent complications and promote healing in mild to severe infections.

Sizing and Forecast

The acute bacterial skin and skin structure infections market size has grown rapidly in recent years. It will grow from $10.57 billion in 2023 to $11.75 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to healthcare industry innovation, economic factors, patient population trends, evolving diagnostic methods, clinical trial innovation..

The acute bacterial skin and skin structure infections market size is expected to see strong growth in the next few years. It will grow to $17.17 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to global epidemiological factors, market entry of new therapies, rapid diagnostic tools, patient-centric approach, shifting treatment guidelines.. Major trends in the forecast period include patient population demographics, antibiotic resistance concerns, advancements in treatment strategies, prevalence of methicillin-resistant staphylococcus aureus (mrsa), focus on outpatient treatment..

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

Segmentation & Regional Insights

The acute bacterial skin and skin structure infections market covered in this report is segmented –

1) By Type Of Infection: Hospital-acquired Acute Bacterial Skin And Skin Structure Infections, Community-acquired Acute Bacterial Skin And Skin Structure Infections
2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients
3) By Route of Administration: Oral, Parenteral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

Major Driver Impacting Market Growth

The rising prevalence of skin infections is expected to propel the growth of the acute bacterial skin and skin structure infections market going forward. Skin infections are conditions in which microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, leading to various symptoms and discomfort. The rise in skin infections creates a greater demand for therapeutic solutions, antibiotics, and innovative treatments to address acute bacterial and skin structure infections, ensuring patients can access the best possible care and outcomes. For instance, in September 2022, according to the UK Health Security Agency (UKHSA), a UK-based national executive agency, the %age of Methicillin-resistant Staphylococcus aureus (MRSA) cases caused by skin and soft tissue infections increased to 33.7% in 2022 from 2021. Moreover, MRSA cases increased by 25.7% in the financial year from April 2020 to March 2021. Therefore, the rising prevalence of skin infections will drive the growth of the acute bacterial skin and skin structure infections market.

Key Industry Players

Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratórios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

The acute bacterial skin and skin structure infections market report table of contents includes:

1. Executive Summary
2. Acute Bacterial Skin And Skin Structure Infections Market Characteristics
3. Acute Bacterial Skin And Skin Structure Infections Market Trends And Strategies
4. Acute Bacterial Skin And Skin Structure Infections Market – Macro Economic Scenario
5. Global Acute Bacterial Skin And Skin Structure Infections Market Size and Growth
.
.
.
32. Global Acute Bacterial Skin And Skin Structure Infections Market Competitive Benchmarking
33. Global Acute Bacterial Skin And Skin Structure Infections Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Acute Bacterial Skin And Skin Structure Infections Market
35. Acute Bacterial Skin And Skin Structure Infections Market Future Outlook and Potential Analysis
36. Appendix